xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Company profile
Ticker
XENE
Exchange
Website
CEO
Simon Pimstone
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
XENE stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
5 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
19 Apr 24
8-K
Other Events
8 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
Transcripts
XENE
Earnings call transcript
2024 Q1
9 May 24
XENE
Earnings call transcript
2023 Q4
29 Feb 24
XENE
Earnings call transcript
2023 Q3
8 Nov 23
XENE
Earnings call transcript
2023 Q2
9 Aug 23
XENE
Earnings call transcript
2023 Q2
9 Aug 23
XENE
Earnings call transcript
2023 Q1
9 May 23
XENE
Earnings call transcript
2022 Q4
1 Mar 23
XENE
Earnings call transcript
2022 Q3
9 Nov 22
XENE
Earnings call transcript
2022 Q2
10 Aug 22
XENE
Earnings call transcript
2022 Q1
10 May 22
Latest ownership filings
144
Notice of proposed sale of securities
12 Jul 24
144
Notice of proposed sale of securities
12 Jun 24
4
GARY PATOU
5 Jun 24
4
Patrick Machado
5 Jun 24
4
Justin D. Gover
5 Jun 24
4
ELIZABETH A. GAROFALO
5 Jun 24
4
STEVEN GANNON
5 Jun 24
4
Gillian Cannon
5 Jun 24
4
Dawn Svoronos
5 Jun 24
144
Notice of proposed sale of securities
5 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 58.90 mm | 58.90 mm | 58.90 mm | 58.90 mm | 58.90 mm | 58.90 mm |
Cash burn (monthly) | 29.92 mm | 884.67 k | 19.68 mm | 18.67 mm | 14.39 mm | 12.84 mm |
Cash used (since last report) | 115.67 mm | 3.42 mm | 76.10 mm | 72.19 mm | 55.65 mm | 49.65 mm |
Cash remaining | -56.77 mm | 55.48 mm | -17.20 mm | -13.29 mm | 3.25 mm | 9.24 mm |
Runway (months of cash) | -1.9 | 62.7 | -0.9 | -0.7 | 0.2 | 0.7 |
Institutional ownership, Q1 2024
97.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 211 |
Opened positions | 85 |
Closed positions | 23 |
Increased positions | 53 |
Reduced positions | 44 |
13F shares | Current |
---|---|
Total value | 2.91 tn |
Total shares | 73.83 mm |
Total puts | 68.90 k |
Total calls | 307.30 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
FMR | 6.60 mm | $284.21 bn |
Avoro Capital Advisors | 5.67 mm | $243.95 bn |
Driehaus Capital Management | 4.32 mm | $186.05 bn |
Wellington Management | 3.92 mm | $168.84 bn |
Capital World Investors | 2.68 mm | $115.44 bn |
Polar Capital | 2.61 mm | $112.45 bn |
Paradigm Biocapital Advisors | 2.48 mm | $106.97 bn |
Capital International Investors | 2.48 mm | $106.59 bn |
Commodore Capital | 2.17 mm | $93.32 bn |
BLK Blackrock | 2.12 mm | $91.35 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jun 24 | Svoronos Dawn | Stock Option Common Shares | Grant | Acquire A | No | No | 38.16 | 15,542 | 593.08 k | 15,542 |
5 Jun 24 | Gannon Steven | Stock Option Common Shares | Grant | Acquire A | No | No | 38.16 | 15,542 | 593.08 k | 15,542 |
5 Jun 24 | Gillian Cannon | Stock Option Common Shares | Grant | Acquire A | No | No | 38.16 | 15,542 | 593.08 k | 15,542 |
5 Jun 24 | Patou Gary | Stock Option Common Shares | Grant | Acquire A | No | No | 38.16 | 15,542 | 593.08 k | 15,542 |
5 Jun 24 | Patrick Machado | Stock Option Common Shares | Grant | Acquire A | No | No | 38.16 | 15,542 | 593.08 k | 15,542 |
News
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
18 Jun 24
Needham Maintains Buy on Xenon Pharmaceuticals, Maintains $62 Price Target
10 May 24
Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
10 May 24
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $50
10 May 24
Xenon Pharmaceuticals Q1 2024 Adj EPS $(0.62) Beats $(0.66) Estimate
9 May 24
Press releases
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
5 Jun 24
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
8 May 24
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
7 May 24
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
2 May 24